Guidelines on screening for hepatitis B virus markers before immunosuppression or chemotherapy
| Society | Who should be screened? | Screening tests |
| AGA | Patients at moderate or high risk of HBVr | HBsAg, anti-HBc + HBV DNA in case of positive results |
| ASCO | Groups at heightened risk for chronic HBV infection or if highly immunosuppressive treatment is planned | HBsAg+- anti-HBc in some populations |
| CDC | All persons receiving cytotoxic or immunosuppressive therapy | HBsAg, anti-HBc, and anti-HBs |
| DGHO | Groups at heightened risk | HBsAg, anti-HBc + HBV DNA in case of positive results |
| ECCO | All IBD patients at diagnosis | HBsAg, anti-HBc, and anti-HBs + HBV DNA in case of positive results |
| EASL | All candidates for chemotherapy and immunosuppression | HBsAg, anti-HBc, and anti-HBs +HBV DNA in case of positive results |
AGA = American Gastroenterological Association; anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; ASCO = American Society of Clinical Oncology; CDC = Centers for Disease Control and Prevention; DGHO = German Society for Haematology and Medical Oncology; EASL = European Association for the Study of the Liver; ECCO = European Crohn´s and Colitis Organisation; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HBV DNA = hepatitis B virus DNA; HBVr = hepatitis B reactivation; IBD = inflammatory bowel disease